239 Days: Oncopeptides' Myeloma Drug Pepaxto Comes Off Market Just Months After Accelerated Approval

 
• By Sue Sutter
Sinking ship
An adverse survival trend in a confirmatory trial sank Pepaxto's chances of remaining on the market • Source: Alamy

More from Drug Safety

More from Pink Sheet